@article{26e1111532e142e58b1d3267cb7ad4bf,
title = "Longitudinally Increasing Elevated Asymmetric Flortaucipir Binding in a Cognitively Unimpaired Amyloid-Negative Older Individual",
abstract = "We present the case of a cognitively unimpaired 77-year-old man with elevated, asymmetric, and longitudinally increasing Flortaucipir tau PET despite normal (visually negative) amyloid PET. His atypical tau PET signal persisted and globally increased in a follow-up scan five years later. Across eight years of observations, temporoparietal atrophy was observed consistent with tau PET patterns, but he retained the cognitively unimpaired classification. Altogether, his atypical tau PET signal is not explained by any known risk factors or alternative pathologies, and other imaging findings were not remarkable. He remains enrolled for further observation.",
keywords = "AV-1451, Alzheimer's disease, Flortaucipir, PET imaging, case reports, tau proteins",
author = "Schwarz, {Christopher G.} and Knopman, {David S.} and Ramanan, {Vijay K.} and Lowe, {Val J.} and Wiste, {Heather J.} and Cogswell, {Petrice M.} and Utianski, {Rene L.} and Senjem, {Matthew L.} and Gunter, {Jeffrey R.} and Prashanthi Vemuri and Petersen, {Ronald C.} and Jack, {Clifford R.}",
note = "Funding Information: The authors give thanks to all the volunteers, participants, and coordinators who contributed to this research. We gratefully thank our funding sources that made this work possible: NIH grants R37 AG011378, R01 AG041851, R01 AG056366, U01 AG006786, P50 AG016574, P30 AG062677, R01 AG034676, R01 NS097495, Gerald and Henrietta Rauenhorst Foundation, Elsie and Marvin Dekelboum Family Foundation, Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic, Liston Award, Schuler Foundation, and Mayo Foundation for Medical Education and Research. We also thank AVID Radiopharmaceuticals, Inc., for their support in supplying AV-1451 precursor, chemistry production advice, and FDA regulatory cross-filing permission and documentation needed for this work. Funding Information: The authors give thanks to all the volunteers, participants, and coordinators who contributed to this research. We gratefully thank our funding sources that made this work possible: NIH grants R37 AG011378, R01 AG041851, R01 AG056366, U01 AG006786, P50 AG016574, P30 AG062677, R01 AG034676, R01 NS097495, Gerald and Hen-rietta Rauenhorst Foundation, Elsie and Marvin This study describes a specific individual participant. To protect that participant{\textquoteright}s privacy, these data will not be shared. In general, data from the Mayo Clinic Study of Aging are made available to qualified academic and industry researchers by request to the Mayo Clinic Study of Aging/Alzheimer{\textquoteright}s Disease Research Center Executive Committee. Publisher Copyright: {\textcopyright} 2022 - The authors. Published by IOS Press.",
year = "2022",
doi = "10.3233/jad-215052",
language = "English (US)",
volume = "85",
pages = "59--64",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "1",
}